Introduction
The temporal and spatial order of cell division is maintained by the activity of cyclin-dependent kinases (CDKs) (Nigg, 1993 (Nigg, , 1995 Nurse et al., 1998; Zhou and Elledge, 2000) whose activity is modulated indirectly by extracellular environmental signals and inhibited by DNA damage checkpoint signals (Hartwell and Weinert, 1989; Morgan, 1995; Zhou and Elledge, 2000) . Mammalian cells express at least six members of the CDK family, which form complexes with their respective cyclin partners to control the transitions between cell-cycle phases. The CDK is the catalytic member of the complex, which associates with a regulatory cyclin whose expression is dependent on the cell-cycle phase. One of the more studied CDK/cyclin complexes is the Cdk1 (Cdc2)/cyclin B1 complex. The initiation of CDK activity requires both phosphorylation by the Cdk-activating kinase kinase on Thr161 (Poon et al., 1993; Solomon et al., 1993) and removal of inhibitory phosphates from Thr14 and Tyr15 on the Cdk1. The Myt1 and Wee1 kinases phosphorylate Thr14 and Tyr15, respectively (Russell and Nurse, 1987; McGowan and Russell, 1993; Mueller et al., 1995; Liu et al., 1997) , and thereby block ATP binding to CDKs and inhibit phosphate transfer to CDK-bound substrates (Atherton-Fessler et al., 1993 : Booher et al., 1997 .
The Cdc25C phosphatase, whose activity is central to mitotic entry, is a dual-specificity phosphatase that directly dephosphorylates and activates the Cdk1/cyclin B kinase complex, leading to the initiation of mitosis. The Cdc25C phosphatase is activated at the G 2 /M transition by phosphorylation on serine and threonine residues. One of the kinases capable of phosphorylating and activating Cdc25 is Cdk1, suggesting the existence of a positive feedback loop. Izumi and Maller (1995) have shown that in interphase Xenopus egg extracts with no detectable Cdk1 and Cdk2, treatment with the phosphatase inhibitor microcystin activated a distinct kinase that could phosphorylate and activate Cdc25. Microcystin also induced other mitotic events such as chromosome condensation and nuclear envelope breakdown in extracts containing less than 5% of the mitotic level of Cdk1 kinase activity. These findings implicate a kinase other than Cdk1 and Cdk2 that can activate Cdc25 in vivo and suggest that this kinase may also phosphorylate M-phase substrates even in the absence of a Cdk1 kinase (Izumi and Maller, 1995) . The Xenopus polo-like kinase (Plk) Plx1 associates with and phosphorylates the amino-terminal domain of Cdc25. When recombinant Plx1 phosphorylates Cdc25 in a purified system, Plx1 stimulates cdc25's activity and results in a strong reaction with MPM-2, a monoclonal antibody directed at mitotic phosphoproteins. These studies indicate that Plx1 may participate in the control of mitotic progression through the regulation of Cdc25 activity (Kumagai and Dunphy, 1996) . Subsequently, Maller's group very elegantly demonstrated that Plx1 is activated in vivo during oocyte maturation with the same kinetics as Cdc25C. Microinjection of wild-type Plx1 into Xenopus oocytes accelerates the rate of activation of Cdc25C and Cdk1/cyclin B. Conversely, microinjection of either an antibody against Plx1 or a kinase-dead version of Plx1 significantly inhibits the activation of Cdc25C and Cdk1/cyclin B. This effect can be reversed by injection of active Cdc25C, indicating that Plx1 is upstream of Cdc25C (Qian et al., 1998) .
Since these initial reports implicating Plx1 in Cdc25 activation, other polo kinases, mainly human polo-like kinase 1 and 3 (Plk1 and Plk3), have been shown to be involved in interactions with Cdc25 (Roshak et al., 2000; Bahassi et al., 2004) . The following review outlines our view of the mammalian Plk3 and its role in mammalian Cdc25 phosphatases regulation.
Plks and cell-cycle regulation
Progress through the various stages of the cell cycle is facilitated and controlled by multiple signaling pathways. Among the many regulatory enzymes that contribute to these processes are the Plks, which are evolutionarily conserved between yeast (Cdc5), Drosophila (Polo), Xenopus (Plx), and mammals (Plk), and which regulate several mitotic events. Mammalian cells express four members of the Plk family, Plk1, 2, 3, and 4. They are important contributors to several cell-cycle events and are identified by their carboxy-terminal polo box (PB) motifs, which are responsible for subcellular localization and substrate recognition (Nigg, 1998; Roshak et al., 2000; Toyoshima-Morimoto et al., 2001; Golan et al., 2002; Sutterlin et al., 2001; Elia et al., 2003; Cheng et al., 2003) . Genetic and biochemical approaches with several organisms indicate that Plks regulate diverse cellular events at various cell-cycle stages. The Xenopus Plx1 is a critical trigger that initiates the onset of the G 2 /M transition Kumagai and Dunphy (1996) , and appears to be part of the Cdk1/cyclin B amplification loop in meiotic maturation of Xenopus oocytes (Karaiskou et al., 2004) . Plx1 also participates in the destruction of targets of the anaphase-promoting complex (APC) to mediate mitotic exit in the early embryonic cell cycle (Brassac et al., 2000) . Genetic studies in Drosophila and yeast indicate that Plks function in centrosome assembly and separation during the formation of the bipolar spindle. Polo mutants in Drosophila display hypercondensed chromosomes, monopolar spindles, disorganized spindle poles, and they manifest abnormal chromosome segregation (Llamazares et al., 1991) . The Schizosaccharomyces pombe plo1 À mutant displays similar phenotypes, such as the formation of monopolar spindles and a failure in septum formation after nuclear division (Ohkura et al., 1995) , and the budding yeast Plk homolog, Cdc5, seems to play an important role in actin ring formation and cytokinesis (Song and Lee, 2001) . Other studies in yeast show that the APC-dependent destruction of Clb2 (cyclin B) depends on Cdc5 activity Jaspersen et al., 1998; Shirayama et al., 1998) . In mammalian cells, Plk1 phosphorylates at least three components of the APC, and in an in vitro-reconstituted system, it activates APC to ubiquitinate cyclin B (Kotani et al., 1998) . More recently, studies have also demonstrated that polo kinase activity plays a pivotal role in the separation of sister chromatids during mitosis (Alexandru et al., 2001) . The yeast Plk, Cdc5, is required to phosphorylate the cohesin subunit Scc1, thereby facilitating its cleavage by separase at the onset of anaphase (Alexandru et al., 2001) . Consistent with this last finding, Plx1 is also a key regulator for the cleavage-independent dissociation of cohesin from chromosomes in Xenopus (Losada et al., 2002) . In mammals, Plks promote spindle formation at G 2 /M, activate APC as cells exit from mitosis, are required for cytokinesis, and are part of the DNA damage checkpoint-signaling cascade in G 2 /M. Plk1 has numerous mitotic functions including the regulation of cyclin B localization. Plk4, also designated Sak, is an essential Plk, which is required for the destruction of cyclin B by the APC and for exit from mitosis in the postgastrulation embryo (Hudson et al., 2001 ). Plk2 and Plk3 are expressed as immediate-early transcripts; however, Plk3 is expressed throughout the cell cycle while Plk2 is only detected in G1 (Simmons et al., 1992; Donohue et al., 1995; Chase et al., 1998; Ma et al., 2003) . In contrast to the other Plks, Plk3 cannot be overexpressed without inducing toxic effects, either through loss of cellular adhesion or induction of apoptosis (Conn et al., 2000) . Here, we propose that one or more Plks may play several additional roles in other phases of the cell cycle. Given the role of Cdc25A in regulating the G 1 /S transition, and recent studies on the function of Cdc25A in S phase, we expect that understanding how Plk3 regulates these phosphatases will soon reveal an expanded role for Plk3 and the other Plks.
The Plk3
In addition to its various functions during the entry into and exit from mitosis, Plk3 also appears to be associated with Golgi breakdown since ectopic expression of Plk3 induces fragmentation of Golgi stacks . Xie et al. (2004) examined functional as well as physical interactions between Plk3 and MEK1/ERK and suggested that Plk3 may be a downstream mediator of MEK1 in the signaling cascade leading to Golgi fragmentation. Furthermore, Wang et al. (2002) reported that Plk3 may play an important role in regulating microtubule dynamics and centrosomal function, and that deregulated expression of Plk3 results in cell-cycle arrest and apoptosis. This observation is consistent with a previous report showing that overexpression of Plk3 in mammalian cells suppresses proliferation and inhibits colony formation, and that overexpression of Plk3 induces chromatin condensation and apoptosis (Conn et al., 2000) . In addition to its nuclear functions, Plk3 clearly has cytoplasmic roles given its involvement in Golgi breakdown . Furthermore, Holtrich et al. (2000) have shown that deregulated Plk3 expression disrupts the cellular Factin network and induces a spherical morphology. In addition, Plk3 binds to the Ca 2 þ /integrin-binding protein Cib in two-hybrid analyses and in co-immunoprecipitation assays (Kauselmann et al., 1999) , and both proteins colocalize in mammalian cells. The homology of Cib with calmodulin and with calcineurin B suggests that Cib might be a Plk regulatory subunit (Holtrich et al., 2000) . Lastly, plk3 is an early inducible gene since plk3 mRNA expression in cultured cell lines is rapidly activated by mitogens (Li et al., 1996) . Clinically, plk3 mRNA expression appears to be downregulated in a majority (26 of 35) of primary head and neck squamous cell carcinomas investigated compared with adjacent uninvolved tissues from the same patients . It is apparent that Plk3 has multiple functions in cellular homeostasis. One key function is the role of Plk3 in the cell cycle and its participation in activating the Cdc25 phosphatases. In this review, we highlight the role of Plk3 in Cdc25 phosphatase regulation.
The Cdc25 phosphatases
The cdc25 gene was first identified as a regulator of the cell cycle in yeast (Hartwell et al., 1974; Nurse, 1975) . Subsequently, homologues of the protein have been identified in most eukaryotic unicellular and multicellular organisms examined. There are three cdc25 genes, cdc25A, B, and C, in the human genome (Gould et al., 1990; Galaktionov and Beach, 1991) , which encode proteins 470-566 residues in length, each of which is composed of two main domains. The aminoterminal portion appears to be a regulatory domain involved in the modulation of enzymatic activity. It has several phosphorylation sites, binding sites for protein partners, alternatively spliced domains, and functionally important domains such as nuclear localization sequences and nuclear exclusion sequences (NES). The three CDC25 proteins are more highly related in the carboxy-terminal half that contains the catalytic domain than in the amino-half of the protein. This includes a Cys-(X)5-Arg motif that is conserved in all dualspecificity phosphatases, and the CH2A and CH2B homology motifs that are also found in MAP kinase phosphatases (Keyse and Ginsburg, 1993) . Crystallographic data, however, show conformational differences in the carboxy-terminal regions of the three CDC25 proteins, suggesting that their catalytic properties may not be identical (Fauman et al., 1998; Reynolds et al., 1999; Wilborn et al., 2001) . The Cdc25 phosphatases are essential regulators of cell-cycle transitions. In lower eukaryotes, Cdc25 is an activator of the G 2 /M transition by virtue of its ability to dephosphorylate the Cdk1 protein kinase (see Draetta and Eckstein, 1997 for a review), while Cdc25 B and C appear to regulate progression from G 2 to M phase (Honda et al., 1993; Mailand et al., 2002) .
Cdc25C phosphatase
Entry into mitosis depends on phosphorylation and activation of the dual-specificity phosphatase Cdc25C, which dephosphorylates and activates the Cdk1/cyclin B complex (Gautier and Maller, 1991; Izumi et al., 1992; Kumagai and Dunphy, 1992; Hoffmann et al., 1993) . Cdc25C is predominantly cytoplasmic during the G1 and S phases in a variety of cell lines (Dalal et al., 1999; Graves et al., 2000) . Its exclusion from the nucleus is dependent on the export protein CRM1 as suggested by its nuclear accumulation following treatment with leptomycin B (Graves et al., 2001) . Human Cdc25C is phosphorylated on serine 216 (S216) and is bound to 14-3-3 proteins throughout interphase (Peng et al., 1997) . Phosphorylation of S216 is required for 14-3-3 binding, and mutation of this serine to alanine abrogates its interaction with 14-3-3 (Peng et al., 1997). Intrinsic nuclear import and export signals, together with 14-3-3 binding, appear to regulate coordinately the intracellular trafficking of Cdc25C (Graves et al., 2001) . When Cdc25C enters the nucleus, it is bound by Pin1, which inactivates Cdc25C phosphatase activity. When Cdc25C is phosphorylated by Xenopus Plx and Cdk1, however, the association with Pin1 increases the phosphatase activity of Cdc25C (Stukenberg et al., 2001) .
Plks in Cdc25C regulation
The interaction between Plks and the Cdc25 phosphatases was initially described in Xenopus. The Xenopus Plk, Plx, is required for small oocytes to re-enter meiosis in response to progesterone (Karaiskou et al., 2004) . Plx was the first Plk shown to be required for the G2/M transition. The Cdk1/cyclin B1 complex increases Plx activation to promote Cdc25 activation and create a positive feedback loop (Abrieu et al., 1998) . Anti-Plx1 antibodies block Cdc25 activity and the consequent Tyr15 dephosphorylation of cdk1/cyclin B (Qian et al., 1998) . Work in starfish embryos indicates that Plk1 may be more important for the inhibition of Myt1, a cdk1/cyclin B complex inhibitor. The starfish embryo Plk1 is activated downstream of cdk1/cyclin B in order to inhibit the activity of Myt1 in meiosis II and meiotic re-entry (Okano-Uchida et al., 2003). The budding yeast polo kinase Cdc5 binds and phosphorylates the Wee1 kinase homolog, Swe1 (Bartholomew et al., 2001) . We have shown that Plk3 phosphorylates serine 191, and to a lesser extent serine 198, within the NES to promote the nuclear accumulation of Cdc25C, and that substitution of serine 191 with an alanine abrogates Cdc25C's nuclear localization (Bahassi et al., 2004) . Further compelling evidence linking Plk3 to Cdc25C accumulation in the nucleus derives from overexpression of Plk3. Transient transfection of cells with wild-type Plk3 but not with a kinase dead Plk3 results in a marked increase of Cdc25C in the nuclear fraction following cell fractionation. This nuclear accumulation is inhibited when Plk3 is suppressed by siRNA, implicating the involvement of Plk3 in the nuclear accumulation of Cdc25C (Bahassi et al., 2004) . Toyoshima-Morimoto et al. (2002) reported that Plk1 phosphorylates Cdc25C on serine 198 to promote its nuclear localization.
Replacement of serine 198 with either an alanine or a phosphomimetic aspartic acid, however, does not result in loss of Cdc25C from the nucleus (Bahassi et al., 2004) . It is likely that disruption of the NES, which contains serine 198, may be sufficient to retain Cdc25C in the nucleus. Since the NES is located in close proximity to the 14-3-3/cyclin B binding domain on Cdc25C, another possibility is that phosphorylation of serines 191 and 198 within the NES inhibits 14-3-3 binding and promotes cyclin B binding. A previous report had argued that Plk3 phosphorylates Cdc25C on serine 216, a result which is inconsistent with the ability of Plk3 to complement a cdc5ts mutant (Ouyang et al., 1997) , but which attributed to a possible role for Plk3 in downregulating cdk1 (p34 cdc2/cdk1 ) activity during late mitosis since considerable Plk3 activity remains during mitosis (Ouyang et al., 1997 ).
An additional relationship between the Plks and the Cdk1/cyclin B complex was described by ToyoshimaMorimoto et al. (2001) . This group reported that Plk1 phosphorylates serine 147 on cyclin B in the middle of its NES and targets it to the nucleus during prophase. They suggested that polo kinases might play a central role in coordinating the nuclear translocation of both Cdc25C and its target Cdk1/cyclin B to the nucleus. The timing of this translocation may be essential for coordinating M-phase events.
Despite recent progress, our understanding of the overlapping and unique roles of the Cdc25 phosphatases and their activating kinases at various cell-cycle transitions remains incomplete. It is somewhat enigmatic, however, that homozygous disruption of Cdc25C in mice yields healthy animals whose cells suffer no mitotic defect, have no alteration of Cdk1 phosphorylation and respond normally to DNA damage (Chen et al., 2001) . It is possible that Cdc25A may compensate for the absence of Cdc25C in these animals since Cdc25A can bind and activate Cdk1-cyclin B, and can accelerate cell division when overexpressed (Chen et al., 2001) . Conversely, when Cdc25A is underexpressed, mitotic entry is delayed (Mailand et al., 2002) .
Cdc25A phosphatase
Cdc25A regulates entry of cells into S phase by dephosphorylating Thr14 and Tyr15 on Cdk2/cyclin E and is required for mitotic progression. Overexpression of Cdc25A promotes a more rapid S-phase entry, while microinjection of anti-Cdc25A antibodies and transfection of Cdc25A antisense oligonucleotides both inhibit S-phase entry (Hoffmann et al., 1994) . Similarly, antisense oligonucleotides directed at cdc25a mRNA inhibited Cdk1/cyclin B activation and mitotic entry (Mailand et al., 2002) .
Cdc25A is regulated at transcriptional and posttranslational levels. The transcription factors E2F1, E2F4, and c-Myc promote the expression of Cdc25A in mid-to late G 1 (Galaktionov et al., 1996; Vigo et al., 1999) , and its activity progressively increases from the G 1 /S transition until mitosis (Blomberg and Hoffmann, 1999) . Although it is expressed continuously, Cdc25A undergoes frequent turnover throughout the cell cycle. Its abundance is regulated by post-translational modification, which either stabilizes it or promotes its degradation (Mailand et al., 2002) . Consequently, Cdc25A has two major peaks of accumulation during cell-cycle progression, one in G1 and the other in S/G2 (Bernardi et al., 2000) .
During S phase and G 2 , the level of Cdc25A is regulated by the ubiquitin ligase SCF (Skp1/Cullin/Fbox) (Donzelli et al., 2002) . The Cdc25A is phosphorylated on Ser82 and Ser88, which mediate binding to the SCF/beta-TrCP complex to promote ubiquitin ligation and Cdc25A degradation (Busino et al., 2003) . Another ubiquitin ligase APC/C (anaphase promoting complex/ cyclosome), in complex with the cdh1 subunit, regulates the level of Cdc25A at mitotic exit and during G1 (Donzelli et al., 2002) . Residual Cdc25A remaining from mitosis is degraded in G1 in response to APC-mediated ubiquitylation. To promote the G1/S transition, transcription of cdc25A is enhanced, and the APC is inactivated.
In addition to the role of Cdc25A to maintain proper cell-cycle progression, its levels are acutely responsive to DNA damage. Damage to DNA promotes Cdc25A degradation, which in turn arrests the cells at the G1/S transition to allow DNA repair. In response to DNA damage, Chk1 and Chk2 kinases phosphorylate Ser123 on Cdc25A to initiate its ubiquitylation and proteosome-mediated degradation (Mailand et al., 2000; Falck et al., 2001) . In the absence of DNA damage, Chk1 phosphorylates Thr507 on Cdc25A to facilitate Cdc25A interaction with 14-3-3 (Chen et al., 2003) . It is likely that this interaction maintains Cdc25A in an inactive form until it is needed to promote the full activation of Cdk1/cyclin B.
Once it was learned that Cdc25A was stabilized during mitosis, the kinases that target Cdc25A and its role in mitosis became a focus of research interest. Prior to mitosis, the Cdk1/cyclin B complex is activated by Cdc25B (Lammer et al., 1998) . This activation allows Cdk1/cyclin B to promote Cdk1-mediated phosphorylation of Ser17 and Ser115 of Cdc25A, which stabilizes Cdc25A and prevents its degradation (Mailand et al, 2002) . Cdk1, however, is not alone in its capacity to phosphorylate and potentially stabilize Cdc25A at mitosis. When the drug roscovitine, a Cdk1 and Cdk2 kinase inhibitor, was used to inhibit Cdk1 and Cdk2 during mitosis, mutants of Cdc25A with altered Cdk1 phosphorylation sites were still phosphorylated. This finding led the authors to speculate that a Plk that was insensitive to the drug might be responsible for Cdc25A stability in mitosis (Mailand et al., 2002) .
Plks in Cdc25A regulation
While most Plks are upregulated and activated at the onset of mitosis, the pattern of expression and activation of Plk3 remains unchanged throughout cell cycle (Bahassi et al., 2002) . This observation led us to speculate about a possible role for Plk3 in regulating other stages of the cell cycle, mainly the G1/S transition through the control of Cdc25A function. In this context, we have identified two Plk3-mediated phosphorylation sites within the carboxy-terminus of Cdc25A (unpublished data). Both sites overlap with the cyclin B binding site on Cdc25A. The potential physiological relevance of phosphorylating these sites includes modulation of Cdc25A association with 14-3-3 or cyclin B, and possible regulation of Cdc25A stability. The protein levels of Cdc25A are stabilized in prometaphase during which a high level of active Cdk1/cyclin B complex is present (Mailand et al., 2002) . Subsequently, Cdk1/ cyclin B activity decreases concomitant with a decrease in Cdc25A (Mailand et al., 2002) . These observations suggest that Cdc25A is required to maintain active Cdk1/cyclin B in the presence of the Myt1 and Wee1 inhibitory kinases until the onset of metaphase and that the activity of Plk3 may be required to facilitate the interaction between cyclin B and Cdc25A until that time.
The phosphorylation of Cdc25A by Plk3 may play yet another role. The cyclin B binding site on Cdc25A is in close proximity to a 14-3-3 binding site for which the residue T507 is essential. Chen et al. (2003) have speculated that Chk1 phosphorylates T507 on Cdc25A throughout the cell cycle. This phosphorylation maintains 14-3-3 binding to Cdc25A and keeps Cdc25A in an inactive state. This type of inhibitory mechanism involving 14-3-3 has been studied for Cdc25B. The Cdc25A and Cdc25B phosphatases share the same residues responsible for binding cyclin B and 14-3-3 to their carboxy-termini. The 14-3-3 protein binds as a dimer to sites within the amino-terminus and the carboxy-terminus of Cdc25B, pulling the two termini together and preventing access to Cdc25B's catalytic domain and nuclear export signal (Giles et al., 2003) . When 14-3-3 is not bound to the amino-terminus, the catalytic site is open and the nuclear export signal is also exposed. The binding of 14-3-3 to Ser323 affects the activity and localization of Cdc25B (Giles et al., 2003) . Other 14-3-3 isoforms have also been shown to affect the function of Cdc25A (Chen et al., 2003) and Cdc25C (Margolis et al., 2003) , but how 14-3-3 is displaced from Cdc25A or Cdc25C remains unknown. One model suggests that Plk3 may mediate binding of cyclin B to the carboxy-terminus of Cdc25A with consequent displacement of 14-3-3, and a similar mechanism may apply to Cdc25B since it also acts as a substrate for Plk3 (Ouyang et al., 1999) .
Conclusions
Based on a BLAST search (Altschul et al., 1990) , the Polo-box domain (PBD) appears to be a domain that is unique to Plks and absent from other proteins. Since it is not a modular domain represented in other proteins, its function may be involved in activities such as intracellular localization and the intramolecular regulation of Plk kinase activity. Recent resolution of the structure of the PBD (Leung et al., 2002; Cheng et al., 2003) opens up the possibility of defining targeted mutations to probe cellular function and the opportunity to design peptidomimics that might inhibit the function of Plks in tumor cells. It is worth noting that microinjection of anti-Plk1 antibodies severely impairs the ability of cells to divide, but distinguishes between transformed and nontransformed cells (Lane and Nigg, 1996) . HeLa cells responded to Plk1 inhibition by mitotic catastrophe (Cogswell et al., 2000) . In contrast, nontransformed Hs68 cells arrest primarily as single mononucleated cells in G 2 (Cogswell et al., 2000) . Presumably, these differences in cell behavior reflect a difference in stringency for the requirement of Plk1 function at the G 2 /M transition. This differential response between transformed and nontransformed cells to Plk1 inhibition is suggestive of Plk1 and other Plks as selective targets for potential anticancer therapeutic purposes.
